 Zidovudine management primary infection Eleven subjects clinical illness characteristic primary infection zidovudine median period days range days Primary infection subject seroconversion virus isolation acute phase illness median days range days commencement zidovudine Six symptoms side-effects zidovudine common nausea subjects headache Treatment subject persistent headache nausea Haemoglobin haematocrit erythrocyte counts mean corpuscular volume treatment None subjects anaemia none dose modification blood transfusion result haematological side-effects significant differences granulocyte count lymphocyte count week treatment baseline levels significant differences T-cell subset numbers subjects treatment group historical controls several subjects termination zidovudine treatment results investigation zidovudine safe drug people primary infection clear evidence clinical benefit terms resolution acute illness indication treatment development persistent infection